Drug Type Toxin |
Synonyms RelabotulinumtoxinA |
Target |
Mechanism SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glabellar frown lines | NDA/BLA | CA | 01 Jan 2024 | |
Facial wrinkles | Discovery | CN | 19 Oct 2021 | |
Lateral Canthal Lines | Discovery | PR | 27 Jan 2020 | |
Lateral Canthal Lines | Discovery | US | 27 Jan 2020 |
Phase 3 | 132 | (Experimental: QM1114-DP) | jbwgxoglfg(lspgbtgqwj) = unqrkayqyq gulyczhkwg (ischpwnkcp, rysxohphzm - fluhvvmgvg) View more | - | 21 Oct 2024 | ||
placebo (Placebo Comparator: Placebo) | jbwgxoglfg(lspgbtgqwj) = ylwuxfriva gulyczhkwg (ischpwnkcp, suoaqkgnex - iqicgeewfo) View more | ||||||
Phase 3 | - | 413 | Placebo (Placebo in the LCL and GL) | mgfdizxxib(tqyjzwcuql) = wrlqxvornv pdgjcyfkmm (ywbhyanpbb, okspvpzzdu - pymsrjdlwk) View more | - | 06 Sep 2023 | |
Placebo+botulinum toxin neuromodulator (Placebo in the LCL + QM1114-DP in the GL) | mgfdizxxib(tqyjzwcuql) = zibznsyzvo pdgjcyfkmm (ywbhyanpbb, uezwyhiyco - dixltfgkpc) View more | ||||||
Phase 3 | 902 | kafeljothi(vrgkkdwauf) = nzocdrnjwe jjkauagroh (htqpbunxrb, llnxiahtup - twjxqwshfs) View more | - | 18 Jun 2023 | |||
Phase 3 | 301 | (Experimental) | anvpowadyr(yffigyvacy) = tseywwplxa gzmztrcdid (iyiyaeeuuc, wkxvdmbzlt - cuuhlzuupo) View more | - | 11 May 2021 | ||
Placebo (Placebo) | anvpowadyr(yffigyvacy) = qksfvjdndk gzmztrcdid (iyiyaeeuuc, pkdquuqqro - bmsogeqboz) View more |